Duffy, Austin
Mater Misericordiae University Hospital
4 papers on CoChatORCID 0000-0001-9277-0157
Most cited papers
- Verified
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 6,645
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
Deming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs
Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Cited by 52
- Verified
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut
Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis
Cited by 24
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free